Technologies
PDF


WARF: P04405US

Device That Rapidly Detects and Characterizes Interactions Between a Drug and Potential Protein Target


INVENTORS -

Martin Zanni, John Wright, Eric Fulmer

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a device that detects and characterizes interactions between two molecules, such as a drug and a potential protein target, under conditions similar to in vivo conditions.
OVERVIEWIdentification and characterization of promising target molecules often presents a bottleneck in the search for new drugs. A variety of high throughput methods for probing protein interactions have emerged over the last few years; however, these methods are slow, unable to effectively detect transient binding interactions that occur on microsecond or shorter time scales, and/or require relatively large amounts of sample (0.1 to 1 milliliter).
THE INVENTIONUW-Madison researchers have developed a device that detects and characterizes interactions between two molecules, such as a drug and a potential protein target, under conditions similar to in vivo conditions. This device can quickly detect transient interactions and requires little sample.

The device uses two laser beams, each with a frequency that can be tuned to the drug or the target biomolecule. If the drug binds to the protein target, it changes the signal beam. The resulting signal can then be measured to determine if the two molecules interact and to assess the strength of binding.
APPLICATIONS
  • High throughput screening for drug discovery
KEY BENEFITS
  • Extremely rapid – detection occurs in microseconds to milliseconds
  • Requires less than 50 nanomoles of sample
  • Capable of detecting transient interactions that occur on sub-millisecond time scales
  • Does not require fluorescent labeling
  • Drugs can be screened for proteins with binding sites that are deep within the biomolecule.
  • When an infrared laser beam is used, isotope labeling can be used to enhance sensitivity while maintaining the ability to detect interactions with deep binding sites.
  • Compatible with high throughput and rational, structure-based approaches to drug discovery and optimization
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Mark Staudt at mstaudt@warf.org or 608-960-9845.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.